The marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and could speed ...

May 11 (Reuters) - Britain's GSK said on Monday it signed a deal with Hong Kong-listed Sino Biopharmaceutical to expand its ...

Countries are making measurable progress in combatting viral hepatitis, but the disease remains a major global health ...

GSK plc GSK on Monday entered into an exclusive strategic collaboration with Sino Biopharmaceutical (SBP Group), through its ...

May 11 (Reuters) - GSK said on Monday it had entered into a strategic collaboration with Hong Kong-listed Sino ...

Tonight, a parent will look down at her newborn and say: let’s wait. The virus will not. Neither will the bleed.

The decision by the Centers for Disease Control and Prevention (CDC) to stop recommending giving infants a dose of the hepatitis B vaccine within 24 hours after birth is likely to lead to hundreds of ...

The agreement with Sino Bio, via its subsidiary Chia Tai Tianqing Pharma (CTTQ), allies GSK with a company that is one of ...

HBV infection at birth or during early infancy can lead to lifelong health problems such as chronic liver disease and liver ...

FDA regulatory momentum includes priority review and breakthrough therapy designation for a potential first-in-class CHB ...

CLEVELAND - A family physician pressed Health and Human Services Secretary Robert F. Kennedy Jr. Thursday on one of the most ...

US model study suggests a targeted hepatitis B birth-dose strategy could increase neonatal infections unless screening and ...